Home | Publications | Diseases | Diabetes place holder
place holder place holder

Diabetes

Diabetes Market Outlook to 2011; The


Publication Date   May 2006
Publisher   Business Insights
Product Type   Report
Pages   176
ISBN Number   not applicable
Product Code   RBI099
Ask a question about this product?

Price £1,495.00

approximately: $2,640 | €1,896

Summary


Diabetes mellitus is a chronic metabolic disorder that is caused by a failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin; type 1 diabetes occurs most often in children or young adults and accounts for 5-10% of the diagnosed diabetes patient population. Type 2 diabetes, or adult-onset diabetes, accounts for 90-95% of diagnosed diabetes cases worldwide, typically developing in middle-aged adults.

There are several risk factors associated with type 2 diabetes including age, obesity, high blood pressure, genetics, level of exercise, and a history of cardiac disease. Type 2 diabetes is more prevalent than type 1 and is growing at a faster rate across the 7 major markets, with a forecast prevalence of 49.2m people in 2011, compared to 39.4m people in 2005. Drivers for increased type 2 prevalence include the aging demographic profile and an increase in obesity. Diabetes is the sixth leading cause of death in the US (based on number of death certificates, NIDDK).

The global diabetes market was worth $18.6bn in 2005, which was an 11.5% increase from 2004 sales of $16.6bn. The US has the dominant share in the global diabetes market, with 49.6% of 2005 global sales. The large US market share is mainly due to the large population and the high prevalence of diabetes, the increasing incidence of diabetes associated with Western diets and an aging population. OADs represent 58% of the global diabetes market in 2005, with the remainder of sales being from insulins and analogs (40.1%) and other drugs with 1.9%.

However, insulins and analogs have seen the largest sales growth at 17.3% in 2005. There has been a high level of innovation in drug delivery technology within the diabetes market during 2005-6. Key events include advances in inhaled insulins, funding into insulin pills, patch technology and pain free needles for injection. The top 10 leading antidiabetic brands consist of 6 OADs (Actos, Avandia, Amaryl, Basen, metformin HCl, and Avandamet) and 4 insulins (Lantus, Humalog, NovoLog/NovoRapid and Novolin 70/30/actraphane).

Content


  • Executive Summary
    • Patient Potential
    • Global Market Analysis
    • Analysis Of Potential Future Blockbusters
    • Leading Players In The Global Diabetes Market
  • Chapter 1 Patient Potential
    • Summary
    • Introduction
    • Disease Description
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Diabetic Complications
    • Prevalence Of Diabetes
    • Type 1
    • Type 2
    • Incidence
    • Mortality
    • Diagnosis
    • Treatment
  • Chapter 2 Global Market Analysis
    • Summary
    • Introduction
    • Market Analysis By Country
    • Anti-Diabetic Licensing Trends
    • Antidiabetic Drug Classes
    • Leading Brands In The Global Diabetes Market
    • Key Events In The Global Diabetes Market, 2005-6
    • Introduction
    • Product Launches And Discontinued Products
    • Reported Side Effects Of Marketed Drugs
    • Innovation In Glucose Testing
    • Cell Transplantation And Innovative Therapies
    • Innovation In Drug Delivery Technology
    • The Insulin Market
    • Human Insulins
    • Fast-Acting Insulin Analogs
    • Intermediate Insulin Analogs
    • Long-Acting Insulin Analogs
    • Intermediate And Fast-Acting Insulin Analogs
    • Intermediate And Long-Acting Insulin Analogs
    • Animal Insulins
    • Insulin Devices
    • Sales Forecast For Human Insulin And Analogs
    • Oral Anti-Diabetics (Oads)
    • Thiazolidiniones (Tzds)
    • Sulfonylureas
    • Biguanides
    • Combined Sulphonylurea And Biguanide Antidiabetics
    • Alpha-Glucosidase Inhibitors
    • Thiozolidiniones (Tzds) And Other Oral Antidiabetics
    • Other Oral Antidiabetics
    • Sales Forecast For Oads
    • Other Drugs
  • Chapter 3 Analysis Of Potential Future
    • Blockbusters
    • Summary
    • Introduction
    • Key Trends In R&d
    • Non-Invasive Human Insulin
    • New Drug Classes In The Oad Market
    • Profiles Of Key Insulin Pipeline Compounds
    • Inhaled Insulins
    • Exubera
    • Aerx Idms
    • Air
    • Oral Insulin
    • Oralin
    • Emisphere Oral Insulin
    • Him2
    • Insulin Patches
    • Profiles Of Key Oad Pipeline Products
    • Dual Ppar Agonists
    • Pargluva
    • Glp-1 Agonists And Dpp Iv Agonists
    • Byetta
    • Galvus
    • Sitagliptin
    • Amylinomimetic Agents
    • Product Forecasts
    • Factors Affecting Forecasts
    • New Product Launches
    • Patent Expiry Dates
    • Clinical Trial Results
    • Human Insulin Sales Forecasts
    • Oad's Sales Forecasts
  • Chapter 4 Leading Players In The Global
    • Diabetes Market
    • Summary
    • Introduction
    • Novo Nordisk
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Novorapid/ Novolog
    • Novolin/Insulatard/Actrapid/Mixtard
    • Prandin/Novonorm
    • Levemir
    • R&d Pipeline Analysis
    • Novomix 50 & 70
    • Aerx Idms/ Nn1998
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Takeda
    • Antidiabetic Sales Focus
    • Marketed Diabetes Product Portfolio
    • Actos
    • Basen
    • Tcv-116
    • Tak-428
    • Tak-128
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Sanofi-Aventis
    • Antidiabetic Sales Focus
    • Marketed Diabetes Product Portfolio
    • Lantus
    • Amaryl
    • R&d Pipeline Analysis
    • Acomplia
    • Exubera
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Glaxosmithkline
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Avandia
    • Avandamet
    • R&d Pipeline Analysis
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Eli Lilly
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Humalog
    • Humulin
    • Actos
    • R&d Pipeline Analysis
    • Arxxant
    • Pulmonary Insulin (Air)
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Servier
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Diamicron
    • R&d Pipeline Analysis
    • S-15261
    • Glufast
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Merck Kgaa
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Glucophage
    • Glucophage Xr
    • Glucovance
    • R&d Pipeline Analysis
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Bayer
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Precose
    • R&d Pipeline Analysis
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Novartis
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • Starlix
    • Metformin Hcl
    • R&d Pipeline Analysis
    • Galvus
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
    • Bristol-Myers Squibb
    • Antidiabetic Sales Focus
    • Marketed Product Portfolio
    • R&d Pipeline Analysis
    • Pargluva
    • Strategic Analysis
    • Drivers Of Growth
    • Resistors Of Growth
  • Chapter 5 Appendix
    • Ims Data
    • Index
  • List Of Figures
    • Figure 1.1: Estimated Number Of New Cases Of Diagnosed Type 2 Diabetes In People Aged 20 Or Over, By Age Group In The Us, 2005
    • Figure 1.2: Diabetes Mortality In The Us, 1999-2003
    • Figure 2.3: Global Diabetes Market Share By Geography, 2005
    • Figure 2.4: Sales Of Types Of Antidiabetic Brands, 2004-5
    • Figure 2.5: Breakdown Of Global Diabetes Sales By Drug Class, 2004-5
    • Figure 2.6: Competitive Dynamics Of The Leading 10 Brands In The Global Diabetes Market, 2004-5
    • Figure 2.7: Innovation In Drug Delivery Technology, 2005-6
    • Figure 2.8: Competitive Dynamics Of The Global Insulin Market, 2004-5
    • Figure 2.9: Competitive Dynamics Of Oads In The Global Diabetes
    • Figure 3.10: Positive And Negative Factors Affecting Forecasted Sales Of Antidiabetics
    • Figure 3.11: Expected Patent Expiry Dates For Major Antidiabetics In The Us, Japan And Eu, 2006-2015
    • Figure 4.12: Competitive Dynamics Of The Leading Players In The Global Diabetes Market, 2005
    • Figure 4.13: Novo Nordisk's Antidiabetic Sales, 2005
    • Figure 4.14: Takeda's Antidiabetic Sales, 2005
    • Figure 4.15: Sanofi-Aventis' Antidiabetic Sales, 2005
    • Figure 4.16: Gsk's Antidiabetic Sales, 2005
    • Figure 4.17: Lilly's Antidiabetic Sales, 2005
    • Figure 4.18: Servier's Antidiabetic Sales, 2005
    • Figure 4.19: Merck Kgaa's Antidiabetic Sales, 2005
    • Figure 4.20: Bayer's Antidiabetic Sales, 2005
    • Figure 4.21: Novartis's Antidiabetic Sales, 2005
    • Figure 4.22: Bristol-Myers Squibb's Antidiabetic Sales, 2005
  • List Of Tables
    • Table 1.1: Prevalence Of Overweight And Obese Adults By Country, 2005-11
    • Table 1.2: Prevalence Of Type 1 & 2 Diabetes In The 7 Major Markets, 2004-5
    • Table 1.3: Prevalence Of Type 1 Diabetes In The 7 Major Markets, 2005-11
    • Table 1.4: Prevalence Of Type 2 Diabetes In The 7 Major Markets, 2005-11
    • Table 2.5: Global Diabetes Market Sales By Country/Region, 2001-5
    • Table 2.6: Leading Brands In The Global Diabetes Market, 2004-5
    • Table 2.7: Characteristics Of The Key Types Of Insulin
    • Table 2.8: Fast-Acting Insulin Analogs In The Global Diabetes Market, 2004-5
    • Table 2.9: Intermediate Insulin Analogs In The Global Diabetes Market, 2004-5
    • Table 2.10: Long-Acting Insulin Analogs In The Global Diabetes Market, 2004-5
    • Table 2.11: Intermediate And Fast-Acting Insulin Analogs In The Global Diabetes Market, 2004-5
    • Table 2.12: Intermediate And Long-Acting Insulin Analogs In The Global Diabetes Market, 2004-5
    • Table 2.13: Insulin Devices In The Global Diabetes Market, 2004-5
    • Table 2.14: Human Insulin And Analogs Sales Forecast, 2005-11
    • Table 2.15: Thiazolidiniones In The Global Diabetes Market, 2004-5
    • Table 2.16: Sulfonylureas In The Global Diabetes Market, 2004-5
    • Table 2.17: Biguanides In The Global Diabetes Market, 2004-5
    • Table 2.18: Combined Sulphonylurea And Biguanide Antidiabetics In The Global Diabetes Market, 2004-5
    • Table 2.19: Alpha-Glucosidase Inhibitors In The Global Diabetes Market, 2004-5
    • Table 2.20: Glitazone And Other Oral Antidiabetics In The Global Diabetes Market, 2004-5
    • Table 2.21: Other Oral Antidiabetics In The Global Diabetes Market, 2004-5
    • Table 2.22: Oad Sales Forecast, 2005-11
    • Table 2.23: Other Drugs In The Global Diabetes Market, 2004-5
    • Table 3.24: Expected Product Launch Dates, 2005-11
    • Table 3.25: Current Diabetes Trials, 2000-9
    • Table 3.26: Human Insulin And Analogs Sales Forecast, 2005-11
    • Table 3.27: Oad Sales Forecast, 2005-11
    • Table 4.28: Leading Players In The Global Diabetes Market, 2004-5
    • Table 4.29: Novo Nordisk's Diabetes Product Portfolio, 2004-5
    • Table 4.30: Novo Nordisk's Diabetes R&d Product Pipeline, 2006
    • Table 4.31: Takeda's Diabetes Product Portfolio, 2004-5
    • Table 4.32: Takeda's Diabetes R&d Product Portfolio, 2006
    • Table 4.33: Sanofi-Aventis' Diabetes Product Portfolio, 2004-5
    • Table 4.34: Sanofi-Aventis' Diabetes R&d Product Pipeline, 2006
    • Table 4.35: Gsk's Diabetes Product Portfolio, 2004-5
    • Table 4.36: Gsk's Diabetes R&d Product Pipeline, 2006
    • Table 4.37: Lilly's Diabetes Product Portfolio, 2004-5
    • Table 4.38: Lilly's Diabetes R&d Product Portfolio, 2006
    • Table 4.39: Servier's Diabetes Product Portfolio, 2004-5
    • Table 4.40: Servier's Diabetes R&d Product Portfolio, 2006
    • Table 4.41: Merck Kgaa's Diabetes Product Portfolio, 2004-5
    • Table 4.42: Merck Kgaa's Diabetes R&d Product Portfolio, 2006
    • Table 4.43: Bayer's Diabetes Product Portfolio, 2004-5
    • Table 4.44: Bayer's Diabetes R&d Product Pipeline, 2006
    • Table 4.45: Novartis' Diabetes Product Portfolio, 2004-5
    • Table 4.46: Novartis' Diabetes R&d Product Pipeline, 2006
    • Table 4.47: Bristol-Myers Squibb's Diabetes Product Portfolio, 2004-5
    • Table 4.48: Bristol-Myers Squibb's Diabetes R&d Product Pipeline, 2006